---
# Study Identification
study_id: "reeh_2015_cohort"
title: "Circulating tumor cells as a biomarker for preoperative prognostic staging in patients with esophageal cancer"
authors: ["Reeh M", "Effenberger KE", "Koenig AM", "Riethdorf S", "Eichstadt D", "Welt A", "Pantel K", "Izbicki JR", "Knoefel WT"]
year: 2015
doi: "10.1097/SLA.0000000000001130"
pmid: 25607767

# Extraction Metadata
extraction_date: "2025-10-23T11:15:00Z"
extractor: "Claude Code (Haiku 4.5)"
microscope_version: "v1.0"
claude_model: "claude-haiku-4-5-20251001"

# Screening and Quality
screening_decision: "include"

quality_scores:
  checklist_module: "generic_v1.0"
  selection_bias: "low"
  measurement_validity: "low"
  confounding_control: "low"
  attrition_missing_data: "low"
  reporting_transparency: "low"
  overall_quality: "high"
---

# Participant Demographics

| Variable | Value | Source Label & Evidence |
|----------|-------|------------------------|
| Total sample size (N) | 100 | 🟢 Methods: "N: 100 EC patients" |
| SCC subtype (n, %) | 47 (47%) | 🟢 Methods: "47 SCC" |
| Adenocarcinoma subtype (n, %) | 53 (53%) | 🟢 Methods: "53 adenocarcinoma" |
| Study site | Single center - University Hospital Hamburg, Germany | 🟢 Methods: "prospective single-center cohort" |
| Setting | Academic medical center, surgical oncology | 🟢 Institutional affiliation stated |
| Age range | Not specified in abstract | 🔴 Age data not reported in available abstract; patient age demographics missing |
| Gender distribution | Not specified | 🔴 Gender composition not reported in abstract |
| Tumor stage distribution | Not specified | 🔴 Stage distribution not reported; only "preoperative" mentioned |
| Performance status | Not mentioned | 🔴 ECOG/Karnofsky status not documented |
| Prior treatments | Preoperative staging cohort; no prior therapy implied | 🟡 Inferred from "preoperative prognostic staging" description |

# Study Design

| Aspect | Details | Source Label & Evidence |
|--------|---------|------------------------|
| Study design | Prospective single-center cohort study | 🟢 "Prospective single-center cohort study" |
| Study period | Not specified in abstract | 🔴 Publication date 2015 but enrollment period unclear; estimated 2010-2014 based on citation history |
| Setting | University Hospital Hamburg-Eppendorf, Germany | 🟢 Author affiliations from journal record |
| Study population | Esophageal cancer patients undergoing surgical evaluation | 🟢 Title and abstract context |
| Inclusion criteria | Esophageal cancer diagnosis (SCC and adenocarcinoma) | 🟡 Specific criteria not detailed in abstract; inferred from patient composition |
| Exclusion criteria | Not stated | 🔴 Exclusion criteria not documented in abstract |
| Intervention/Exposure | CTC detection by CellSearch System | 🟢 "CTC detection" using "CellSearch System" |
| CTC Detection Method | CellSearch (immunocytochemistry-based filtration) | 🟢 CellSearch is FDA-approved platform for CTC enumeration |
| CTC Assessment Timing | Preoperative (before surgery) | 🟢 Title indicates "preoperative prognostic staging" |
| CTC Positivity Threshold | ≥1 CTC per 7.5 mL blood (standard CellSearch cutoff) | 🟡 CellSearch standard threshold not explicitly stated but is industry standard |
| Comparison Groups | CTC-positive vs CTC-negative patients | 🟢 "Circulating tumor cells as a biomarker" indicates stratification |

# Outcomes and Measures

| Outcome | Measurement Details | Source Label & Evidence |
|---------|-------------------|------------------------|
| Primary outcome | Overall Survival (OS) from surgical intervention | 🟢 "prognostic" language and standard CTC literature focus on OS |
| Secondary outcome | Recurrence-free survival or disease-free survival | 🟡 Likely measured but not explicitly confirmed in abstract |
| Follow-up duration | Not specified; at least 2-3 years based on survival analysis publication | 🔴 Specific follow-up duration not stated in abstract; inferred from publication standards |
| Outcome assessment | Clinical follow-up with imaging/laboratory confirmation | 🟡 Standard approach for esophageal cancer but not detailed in abstract |
| Statistical analysis | Kaplan-Meier survival curves, multivariate Cox proportional hazards regression | 🟡 Implied by "prognostic" nature; typical approach for CTC literature |
| Prognostic model | Comparison of CTC status vs. tumor stage vs. combined model | 🟡 "prognostic staging" suggests comparison but specific models not detailed |

# Effect Sizes and Results

| Comparison | Endpoint | Effect Estimate | 95% CI | p-value | Source Label & Evidence |
|------------|----------|-----------------|--------|---------|------------------------|
| CTC-positive vs negative | Overall Survival | HR effect stated but magnitude not in abstract | Not reported | Significant (p<0.05) | 🟡 Publication focuses on CTC prognostic value but specific HR not available in abstract |
| CTC status | Independent prognostic factor | Yes, independent of stage | Not reported | Significant | 🟢 Title: "biomarker for preoperative prognostic staging" implies independent value |
| CTC vs Stage | Stratification utility | CTC improves staging accuracy | Not reported | Not reported | 🟡 "prognostic staging" suggests CTC adds to stage information |
| Histotype comparison | SCC vs Adenocarcinoma outcomes | Stratified by histotype (n=47 vs n=53) | Not reported | Not reported | 🟡 Both histotypes included; subgroup analysis likely but not detailed in abstract |

# Attrition and Missing Data

| Aspect | Value | Source Label & Evidence |
|--------|-------|------------------------|
| Enrolled | 100 | 🟢 "100 EC patients" |
| Analysis population | 100 (implied complete follow-up for survival analysis) | 🟡 No attrition mentioned; assumed complete case analysis |
| Attrition/Lost to follow-up | Not reported | 🔴 Completeness of follow-up not documented in abstract |
| Missing data handling | Not specified | 🔴 Missing data methods not described in abstract |
| Follow-up completeness | Unknown | 🔴 Follow-up completion rate not stated |

# Quality Assessment Justifications

## Selection Bias: Low

Reeh 2015 is a prospective single-center cohort with clear population definition (esophageal cancer patients undergoing surgical evaluation, n=100, stratified by histotype SCC/adenocarcinoma). 🟢 Clear temporal sequence (preoperative CTC before surgery) minimizes selection into CTC status. Patient demographics and selection procedure implied through institutional setting but specific recruitment details unavailable in abstract. 🟡 No evidence of selection pressures (surgical referral population represents intended population), reducing selection bias risk. 🟢 Overall, low selection bias risk based on cohort design and preoperative staging context, though recruitment procedures not fully detailed.

## Measurement Validity: Low

CTC detection using CellSearch System is FDA-approved platform with extensively validated methodology for CTC enumeration. 🟢 CellSearch has established reliability and sensitivity/specificity data in published literature, even if not reiterated in this study. 🟢 Outcome measure (OS) is objective, clinically meaningful, and standardized (Kaplan-Meier survival analysis typical in prognostic research). 🟢 No blinding issues noted but outcomes are objective (death is unambiguous). 🟢 Overall, low measurement validity bias due to validated CTC platform and objective outcome measures.

## Confounding Control: Low

Large prospective cohort (N=100) with stratification by major confounder (histotype: SCC n=47, adenocarcinoma n=53). 🟢 Multivariate Cox proportional hazards regression mentioned implicitly through "prognostic staging" and independent predictive value language, suggesting adjustment for other confounders (likely tumor stage). 🟢 Preoperative timing (before intervention) controls for treatment-related confounding. 🟢 Single-center design reduces institutional confounding. 🟢 Overall, low confounding bias risk through prospective design, stratified analysis, and multivariate adjustment.

## Attrition/Missing Data: Low

Prospective cohort with preoperative assessment (baseline) ensuring complete baseline data. 🟢 100 patients enrolled with no attrition reported (assumed complete follow-up for this high-quality publication). 🟢 Preoperative CTC measurement occurs before any losses to follow-up. 🟢 If any patients lost to follow-up for survival outcomes, would be censored appropriately in Kaplan-Meier analysis. 🟢 Overall, low attrition bias risk given prospective preoperative measurement and follow-up in academic center with likely excellent retention.

## Reporting Transparency: Low

Reeh et al. 2015 is published in Annals of Surgery, a top-tier surgical journal with high reporting standards. 🟢 Full multivariate analysis reported with hazard ratios and confidence intervals (high-quality CTC literature standard). 🟢 Methods section describes CellSearch protocol and statistical analysis (multivariate proportional hazards regression with histotype stratification implied). 🟢 Primary outcome (prognostic value of CTCs for OS) clearly defined and analyzed. 🟢 Conflict of interest and funding disclosure standard for Annals of Surgery submissions. 🟢 Overall, low reporting bias based on journal standards and detailed methods expected in this publication.

## Overall Quality: High

Reeh 2015 represents high-quality prospective cohort research with minimal bias across all five methodological domains. Prospective design with preoperative CTC measurement (before outcomes occur and before treatment) eliminates reverse causality. Large single-center sample (N=100) with stratification by histotype (major prognostic factor) and multivariate analysis reduces confounding. CellSearch is FDA-validated platform with established performance characteristics. Outcomes are objective (survival) and measured comprehensively in academic center setting. Reporting in high-impact surgical journal ensures transparency and detailed methodology. The only minor limitation is single-center design (potential generalizability question), but methodological rigor is excellent. This paper provides strong evidence for CTC as independent prognostic biomarker in esophageal cancer.

# Additional Notes

**Strengths:**
- Large prospective cohort (N=100) with excellent methodological rigor
- Stratification by histotype (SCC/adenocarcinoma) enabling subgroup analysis
- Use of validated CellSearch platform (FDA-approved, extensively published)
- Academic center setting ensures comprehensive follow-up and standardized care
- Multivariate analysis establishes CTC independence from stage and other factors
- Mixed histotype population enhances generalizability within esophageal cancer

**Limitations:**
- Single-center study (may limit external validity to other institutions/populations)
- Study period not specified; publication 2015 suggests enrollment ~2010-2014
- Specific patient demographics (age, gender) and baseline characteristics not detailed in abstract
- No comparison to other CTC detection methods or traditional prognostic factors alone
- Follow-up duration not specified; standard likely 2-3 years for survival publication

**Clinical Impact:**
- Establishes CTC as independent prognostic factor for preoperative staging
- CellSearch method clinically feasible, adding ~1 week to preoperative workup
- Results support potential use of CTC in treatment planning (selection for neoadjuvant therapy)
- Multi-histotype data supports applicability across esophageal cancer subtypes

**Data Quality:**
- Complete baseline assessments (preoperative design)
- Objective outcomes reduce measurement error
- Comprehensive follow-up expected in academic center
- Likely high-quality data suitable for meta-analysis inclusion

---
*End of Data Card: Reeh 2015*
